{"filing":{"accession_number":"0001823239-26-000056","cik":"0001823239","ticker":"MRVI","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"mrvi-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000056/mrvi-20260806.htm"},"events":[{"id":25984,"run_id":23596,"accession_number":"0001823239-26-000056","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release for Q2 2026 financial results. The filing discloses quarterly revenue of $51.4 million, net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million, along with updated full-year 2026 guidance raising Adjusted EBITDA guidance to $33–$35 million. The press release is furnished as Exhibit 99.1 and is the primary disclosure under Item 2.02, which is the standard Item for earnings announcements.","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26946,"accession_number":"0001823239-26-000056","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 financial results. The filing discloses quarterly revenue of $51.4 million, net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million, along with updated full-year 2026 guidance raising Adjusted EBITDA guidance to $33–$35 million. The press release is furnished as Exhibit 99.1 and is the primary disclosure under Item 2.02, which is the standard Item for earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:52:27.649171+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26946,"accession_number":"0001823239-26-000056","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 financial results. The filing discloses quarterly revenue of $51.4 million, net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million, along with updated full-year 2026 guidance raising Adjusted EBITDA guidance to $33–$35 million. The press release is furnished as Exhibit 99.1 and is the primary disclosure under Item 2.02, which is the standard Item for earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:52:27.649171+00:00","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","filing_date":"2026-08-06"}]}